Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension†
- 1 February 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 9 (2) , 265-268
- https://doi.org/10.1002/hep.1840090217
Abstract
It has recently been reported that the administration of ketanserin, a serotonin antagonist, was associated with a significant reduction in portal pressure both in portal hypertensive rats and cirrhotic patients. However, this beneficial effect on splanchnic hemodynamics was accompanied by a significant reduction in arterial pressure. Using conscious dogs, we investigated the effect of the chronic oral administration of a new specific antiserotonergic drug, ritanserin (10 mg per day for 5 days), on portal pressure and systemic hemodynamics. Eleven dogs with secondary biliary cirrhosis and portal hypertension due to chronic bile duct ligation were evaluated. One week prior to study, heparinized catheters were placed in the portal vein and brought subcutaneously to the dorsal cervical area. Measurements were made under baseline conditions, following ritanserin administration and 72 hr after the last dose. Ritanserin administration caused a significant reduction in portal pressure (from 17.3 ± 3.1 mmHg to 13.6 ± 4.5 mmHg; mean decrease: 23.1%; p<0.001). Maximal effects on portal pressure were reached on the fourth day. During the recovery period, hemodynamic parameters returned to baseline values. In six of the 11 cirrhotic dogs with successful chronic catheterization of the inferior vena cava and aorta, ritanserin administration did not cause significant changes in the mean arterial pressure, heart rate, cardiac output and peripheral vascular resistance. These data indicate that chronic implantation of venous and arterial catheters in dogs with secondary biliary cirrhosis is a useful experimental model for pharmacological studies of portal hypertension in conscious animals. The selective effect of ritanserin on portal pressure of portal hypertensive dogs indicates that this drug may be of value in the medical treatment of portal hypertension.This publication has 14 references indexed in Scilit:
- Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotonergic mechanisms in portal hypertensionHepatology, 1987
- Hypersensitivity of mesenteric veins to 5‐hydroxytryptamine‐ and ketanserin‐induced reduction of portal pressure in portal hypertensive ratsBritish Journal of Pharmacology, 1986
- Effect of Propranolol on Hepatic and Systemic Hemodynamics in Dogs With Chronic Bile Duct LigationHepatology, 1986
- 200 years of digitalis: the emerging central role of the sodium ion in the control of cardiac forceAmerican Journal of Physiology-Cell Physiology, 1985
- The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus LorazepamPharmacopsychiatry, 1985
- Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- Effect of Two Models of Portal Hypertension on Splanchnic Organ Blood Flow in the RatClinical Science, 1985
- Increased Blood Flow Through the Portal System in Cirrhotic RatsGastroenterology, 1984
- Chronic Bile Duct Ligation in the Dog: Hemodynamic Characterization of a Portal Hypertensive ModelHepatology, 1983
- A COMPARISON OF THE EFFECTS OF BRADYKININ, 5‐HYDROXYTRYPTAMINE AND HISTAMINE ON THE HEPATIC ARTERIAL AND PORTAL VENOUS VASCULAR BEDS OF THE DOG: HISTAMINE H1 AND H2‐RECEPTOR POPULATIONSBritish Journal of Pharmacology, 1977